# Biotechnology Value Fund

> Biotechnology Value Fund is a VC fund backing Biotechnology and Health Care. See 102 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: San Francisco, United States
- Total investments: 102
- Last investment: Sep 2023
- Lead investor: 22%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/bvf-partners-l.p
- Website: http://www.bvflp.com

Biotechnology Value Fund is a VC fund in San Francisco focused on Biotechnology and Health Care. Biotechnology Value Fund, L.P. is an evergreen fund specializing in early stage financing. It focuses on undervalued investment

## Contacts

5 contacts available for Biotechnology Value Fund. Shizune tracks 8 team members at Biotechnology Value Fund. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/bvf-partners?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 76 | 75% |
| Health Care | 44 | 43% |
| Pharmaceutical | 35 | 34% |
| Therapeutics | 34 | 33% |
| Medical | 27 | 26% |

16 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 31 | 30% |
| Post-IPO Equity | 28 | 27% |
| Series A | 14 | 14% |
| Series C | 13 | 13% |
| Venture - Series Unknown | 4 | 4% |

12 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 65 | 64% |
| Switzerland | 4 | 4% |
| Canada | 3 | 3% |
| China | 1 | 1% |
| France | 1 | 1% |

9 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Gorjan Hrustanovic | Managing Director | 8 | https://shizune.co/investors/profile/gorjan-hrustanovic |
| James Kratky | Chief Financial Officer, Chief Compliance Officer | 0 | https://shizune.co/investors/profile/james-kratky-fa8b |
| Mark Nathan Lampert | President, CEO/Founder | 2 | https://shizune.co/investors/profile/mark-nathan-lampert |
| Matthew Perry | Portfolio Manager | 0 | https://shizune.co/investors/profile/matthew-perry |
| Michael Murray | Managing Director | 0 | https://shizune.co/investors/profile/michael-murray-7 |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Olema Oncology | Olema is a preclinical biotechnology company developing new drugs for the treatment and prevention of estrogen receptor (ER) positive breast cancer.The company focuses on the discovery, development, and commercialization of targeted therapies for women's cancers. It leverages the knowledge of the molecular action of the ER to designcompounds that are superior to both the current drugs and those in development.Olema leverages their deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance with the goal of transforming the standard of care for pre- and post-menopausal women living with cancer by developing more convenient and effective therapies. | $130M | Post-IPO Equity | Sep 05, 2023 |  |
| Crossbow Therapeutics | Crossbow Therapeutics is a seed-stage, stealth-mode oncology startup company. The company develops antibody engineering for intracellular cancer targets. | $80M | Series A | Jul 11, 2023 |  |
| Septerna | Septerna is a biotechnology company. | $150M | Series B | Jul 11, 2023 |  |
| Quanta Therapeutics | Quanta is a biotechnology company uncovering novel cancer therapeutic candidates using allosteric modulation to target driver oncogenes. The company was founded in 2018 and is based in San Francisco, CA. | $50.7M | Series D | May 22, 2023 |  |
| Delcath Systems | Delcath Systems and its proprietary targeted drug delivery system are at the forefront of the regional treatment of cancer. The Company's technology, known as Percutaneous Hepatic Perfusion (PHP), allows physicians to deliver significantly higher doses of anti-cancer drugs to the site of disease without exposing the patient's entire bodyto those same potent levels of drug. Initial clinical results from studies treating cancer in the liver confirm that delivering more drug to the tumor site, and less to the other regions of the body, enhances tumor shrinkage with improved quality of life over systemic cancer therapies. PHP is currently undergoing testing in Phase III and Phase II clinical trials for a variety of cancers of the liver. | $85M | Post-IPO Equity | Mar 27, 2023 |  |
| Unicycive Therapeutics | Unicycive Therapeutics provides development programs that focus on treating kidney diseases with significant unmet medical needs. It aims to open the way for a broad range of disease-modifying therapies by modifying the intracellular and extracellular concentrations of these various electrolytes and ions in Chronic Kidney Disease and Gitelman’sSyndrome and by addressing the underlying mitochondrial pathology and inflammation associated with Acute Kidney Disease.Unicycive Therapeutics was founded in 2016 and is headquartered in Los Altos, California. | $30M | Post-IPO Equity | Mar 06, 2023 |  |
| Verastem Oncology | Verastem Oncology is a biopharmaceutical company committed to the development and commercialization of medicines to improve the lives of patients diagnosed with cancer. Its portfolio consists of small molecule kinase inhibitors that inhibit critical signaling pathways, which promote cancer cell survival and tumor growth. | $60M | Post-IPO Equity | Jan 24, 2023 |  |
| Palvella Therapeutics | Palvella Therapeutics is a start-up life sciences company that focuses on relentlessly and selflessly serving abandoned patient populations with therapies. The company specializes in developing therapies that specifically target the root cause of the disease. Palvella Therapeutics was founded in 2015 and headquartered in Wayne, Pennsylvania. | $37.7M | Series D | Jan 05, 2023 |  |
| Alpha-9 Oncology | Alpha9 Theranostics is a clinical-stage biopharmaceutical company. | $75M | Series B | Dec 14, 2022 |  |
| NewcelX (formerly NLS Pharma) | NLS Pharma is a clinical-stage drug development company focusing on neurobehavioral and neurocognitive disorders and their pharmacognosia. Its patient-centered approach increases the rate for success and our successful collaboration with experts across industry, academia allows for a target specific and customized approach. | $10M | Post-IPO Equity | Dec 07, 2022 |  |

10 of 102 investments shown.

## Co-investors
- [Biotechnology Value Fund](https://shizune.co/investors/profile/biotechnology-value-fund) — VC Fund, 102 deals together
- [Biotechnology Value Fund](https://shizune.co/investors/profile/bvf-partners-3e10) — VC Fund, 66 deals together
- [Logos Capital](https://shizune.co/investors/profile/logos-capital) — VC Fund, 33 deals together
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund, 28 deals together
- [Janus Henderson Investors](https://shizune.co/investors/profile/janus-henderson-investors) — VC Fund, 22 deals together
- [Surveyor Capital](https://shizune.co/investors/profile/surveyor-capital) — VC Fund, 21 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Biotechnology Value Fund invest in?

Biotechnology Value Fund invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Series B and Post-IPO Equity stage. Most of the 102 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Biotechnology Value Fund?

Public channels for Biotechnology Value Fund include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Biotechnology Value Fund?

The team at Biotechnology Value Fund includes Gorjan Hrustanovic (Managing Director), James Kratky (Chief Financial Officer, Chief Compliance Officer) and Mark Nathan Lampert (President, CEO/Founder), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co